| Drug Name: | Mefenamic acid (61-68-7) |
|---|---|
| PubChem ID: | 4044 |
| SMILES: | CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O)C |
| InchiKey: | HYYBABOKPJLUIN-UHFFFAOYSA-N |
| Therapeutic Category: | Analgesics, Anti-Inflammatory Agents, Antirheumatic Agents, Cyclooxygenase Inhibitors, Enzyme Inhibitors, Peripheral Nervous System Agents, Sensory System Agents |
| Molecular Weight (dalton) | : | 241.29 |
| LogP | : | 3.74524 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 2 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 49.33 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Ciprofloxacin (85721-33-1) | Neurotoxicity | Antagonistic | Not fully understood Experiments in mice have shown that quinolones competitively inhibit the binding of gamma-amino butyric acid (GABA) to its receptors the NSAID simply lowers the amount of quinolone needed to precipitate convulsions in already susceptible individuals | Hippocampus and frontal cortex are the potential mediatory sites for convulsions induced by new quinolones and non-steroidal anti-inflammatory drugs |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category